BOSTON--(BUSINESS WIRE)--Sengenics LLC, driving the discovery of next-gen biomarkers, announces that Jerry Williamson has been appointed the company’s Chief Executive Officer, effective immediately. With more than 30 years of experience in bioscience markets for life science research, diagnostics and analytical products, Mr. Williamson promises to build on Sengenics’ growth in the fields of immunology, immuno-oncology, neurological disease, and precision medicine.
Mr. Williamson takes over today from Sengenics’ long-time CEO Arif Anwar, Ph.D., who co-founded Sengenics in 2008 with Chief Scientific Officer Jonathan Blackburn, Ph.D. Dr. Anwar said that Mr. Williamson is a natural fit for leading the company into the next phase of growth. “With Sengenics’ renewed focus on precision medicine and a North America base, the time was right to step down from my leadership role and welcome Jerry to the exemplary team we have built over the last 14 years. Jerry’s experience in scaling top global biotech businesses, regulatory landscapes and his passion for technology and driving commercial teams forward is unparalleled.” Dr. Anwar will stay on in an advisory role through the transition and will remain on Sengenics’ Board of Directors.
Prior to his most recent role as CEO and Board Director of NanoView Biosciences, Mr. Williamson was President, CEO and Board Director of Kew, Inc. and held senior positions at Metamark Genetics, Flagship Ventures, Molecular Devices (Danaher), Biacore (GE) and Pyrosequencing (QIAGEN). A proven visionary in the life sciences arena, Mr. Williamson is eager to put his wide-ranging experience to work. “I am honored for the opportunity to lead the team at Sengenics and continue to build upon the successes, work, and trajectory that Arif and the team have established. Sengenics has a unique opportunity with the support provided by Summa Equity to provide significant improvements in precision medicine. I look forward to this new journey.”
Mr. Williamson’s arrival comes at an exciting time for the company. Stockholm-based Summa Equity took a majority stake in Sengenics in October 2020, allowing the company to accelerate its assay technologies, scale up its commercial capacity and market awareness. With game-changing protein folding technology, multiplexed autoantibody profiling services and products and advanced customization and bioinformatics capabilities, Sengenics’ platform is driving the discovery of highly predictive autoantibody signatures for diagnosing disease, stratifying patients, and predicting therapeutic response.
Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics. Sengenics is headquartered in Greater Boston, Massachusetts, USA and has offices worldwide. Sengenics has more than 50 employees across its current locations. www.sengenics.com
About Summa Equity
Summa Equity invests in companies that are solving global challenges and creating positive Environmental, Social, and Governance (ESG) outcomes for society. Summa’s purpose is to co-create win-win for investors, portfolio companies, and society through aligning its vision and outcomes to the Sustainable Development Goals, ensuring a net-positive impact against ESG challenges, and the potential for long-term, sustainable outperformance. Investments are focused on industries and companies that have tailwind from megatrends within three sustainability themes: Resource Efficiency, Changing Demographics, and Tech-Enabled Transformation. Across these themes, Summa’s portfolio companies are supporting a world in transition and showing that business can be part of the solution. Summa Equity has c. EUR 4 billion (c. SEK 40 billion) assets under management. www.summaequity.com